PT3027651T - Anticorpos anti-fgfr2iiib não fucosilados - Google Patents

Anticorpos anti-fgfr2iiib não fucosilados

Info

Publication number
PT3027651T
PT3027651T PT14752705T PT14752705T PT3027651T PT 3027651 T PT3027651 T PT 3027651T PT 14752705 T PT14752705 T PT 14752705T PT 14752705 T PT14752705 T PT 14752705T PT 3027651 T PT3027651 T PT 3027651T
Authority
PT
Portugal
Prior art keywords
afucosylated anti
fgfr2iiib antibodies
fgfr2iiib
antibodies
afucosylated
Prior art date
Application number
PT14752705T
Other languages
English (en)
Portuguese (pt)
Inventor
Harding Thomas
Pierce Kristen
Patil Namrata
Brennan Thomas
Hambleton Julie
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51358085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3027651(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of PT3027651T publication Critical patent/PT3027651T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT14752705T 2013-08-01 2014-07-31 Anticorpos anti-fgfr2iiib não fucosilados PT3027651T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361861198P 2013-08-01 2013-08-01
US201361901732P 2013-11-08 2013-11-08
US201461933632P 2014-01-30 2014-01-30

Publications (1)

Publication Number Publication Date
PT3027651T true PT3027651T (pt) 2019-05-31

Family

ID=51358085

Family Applications (2)

Application Number Title Priority Date Filing Date
PT191511476T PT3708583T (pt) 2013-08-01 2014-07-31 Anticorpos anti-fgfr2iiib afucosilados
PT14752705T PT3027651T (pt) 2013-08-01 2014-07-31 Anticorpos anti-fgfr2iiib não fucosilados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT191511476T PT3708583T (pt) 2013-08-01 2014-07-31 Anticorpos anti-fgfr2iiib afucosilados

Country Status (30)

Country Link
US (5) US20150050273A1 (enExample)
EP (3) EP4036118A1 (enExample)
JP (5) JP6860342B2 (enExample)
KR (3) KR102516152B1 (enExample)
CN (2) CN112225810B (enExample)
AU (4) AU2014296174B2 (enExample)
CA (1) CA2915665C (enExample)
CL (2) CL2016000221A1 (enExample)
CY (2) CY1121517T1 (enExample)
DK (2) DK3708583T3 (enExample)
ES (2) ES2913291T3 (enExample)
HR (1) HRP20190502T1 (enExample)
HU (2) HUE043815T2 (enExample)
IL (1) IL243409B (enExample)
LT (2) LT3708583T (enExample)
ME (1) ME03476B (enExample)
MX (2) MX374785B (enExample)
MY (1) MY184628A (enExample)
NZ (1) NZ715201A (enExample)
PE (2) PE20210949A1 (enExample)
PH (3) PH12019501393B1 (enExample)
PL (2) PL3027651T3 (enExample)
PT (2) PT3708583T (enExample)
RS (1) RS58719B1 (enExample)
RU (2) RU2740714C2 (enExample)
SG (1) SG11201600767UA (enExample)
SI (2) SI3027651T1 (enExample)
TW (2) TWI633120B (enExample)
WO (1) WO2015017600A1 (enExample)
ZA (1) ZA201603218B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ715201A (en) * 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
WO2015067547A1 (en) * 2013-11-05 2015-05-14 Roche Diagnostics Gmbh A method for determining the total amount and/or concentration of an analyte in the presence of a binding molecule as well as kits, compositions and uses relating thereto
WO2016171107A1 (ja) * 2015-04-20 2016-10-27 第一三共株式会社 Ｆｇｆｒ２の検出
CA3004794A1 (en) * 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG10202112636SA (en) * 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
EP3625256A1 (en) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
TWI870011B (zh) 2017-08-25 2025-01-11 美商戊瑞治療有限公司 Ｂ７－ｈ４抗體及其使用方法
JP7258038B6 (ja) 2018-02-21 2023-04-25 ファイヴ プライム セラピューティクス インク Ｂ７－ｈ４抗体の投薬計画
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
CN112804989A (zh) * 2018-10-05 2021-05-14 戊瑞治疗有限公司 抗fgfr2抗体制剂
EP3867274A1 (en) 2018-10-15 2021-08-25 Five Prime Therapeutics, Inc. Combination therapy for cancer
CA3160812A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
JP7685999B2 (ja) * 2019-12-24 2025-05-30 ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド 新規抗ＦＧＦＲ２ｂ抗体
CA3160811A1 (en) * 2019-12-24 2021-07-01 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Novel anti-fgfr2b antibodies
MX2022011050A (es) 2020-03-06 2022-12-15 Ona Therapeutics S L Anticuerpos anti-cd36 y su uso para tratar cancer.
EP4232481A1 (en) * 2020-10-22 2023-08-30 Regeneron Pharmaceuticals, Inc. Anti-fgfr2 antibodies and methods of use thereof
US20240101683A1 (en) * 2020-12-29 2024-03-28 Shenzhen Forward Pharmaceuticals Co., Limited Anti-FGFR2 Antibody and Use Thereof
US20250206836A1 (en) 2021-07-30 2025-06-26 ONA Therapeutics S.L. Anti-cd36 antibodies and their use to treat cancer
EP4414387A4 (en) * 2021-10-08 2025-10-29 Shenzhen Forward Pharmaceuticals Co Ltd ANTI-FGFR2 ANTIBODY WITH IMPROVED ADCC AND ITS USE
TW202342527A (zh) 2022-02-25 2023-11-01 美商安進公司 鱗狀非小細胞肺癌之治療
KR20250099773A (ko) * 2022-09-30 2025-07-02 3에이치 파머슈티컬즈 컴퍼니 리미티드 항-fgfr2b 항체 및 이의 용도
CN117917435A (zh) * 2022-10-21 2024-04-23 北京天广实生物技术股份有限公司 结合fgfr2b的抗体及其用途
TW202442679A (zh) * 2022-12-28 2024-11-01 大陸商蘇州創勝醫藥集團有限公司 抗－ｆｇｆｒ２ｂ抗體及其用途
TW202442685A (zh) * 2023-04-28 2024-11-01 大陸商武漢人福創新藥物研發中心有限公司 抗FGFR2b單抗
WO2025103358A1 (en) * 2023-11-14 2025-05-22 Suzhou Transcenta Therapeutics Co., Ltd. Anti-fgfr2b immunoconjugates and their use in the treatment of cancer
WO2025130860A1 (zh) * 2023-12-18 2025-06-26 山东先声生物制药有限公司 抗FGFR2b抗体及其应用
WO2025232811A1 (zh) * 2024-05-09 2025-11-13 正大天晴药业集团股份有限公司 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5981216A (en) 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU638734B2 (en) 1989-07-06 1993-07-08 Regents Of The University Of California, The Receptors for fibroblast growth factors
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6323316B1 (en) 1996-06-18 2001-11-27 The United States Of America As Represented By The Secretary Of The Department Of And Human Services Fibroblast growth factor receptor activating gene 1 and related compositions and methods
PT994903E (pt) 1997-06-24 2005-10-31 Genentech Inc Metodos e composicoes para glicoproteinas galactosiladas
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
EP1034298B1 (en) 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
WO2000025803A1 (en) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparations
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
WO2000064946A2 (en) 1999-04-28 2000-11-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING A POLYPEPTIDE
JP2001302699A (ja) 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆｒに対する抗体
EP3263702A1 (en) 2000-10-06 2018-01-03 Kyowa Hakko Kirin Co., Ltd. Cells producing antibody compositions
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
CN101357943A (zh) * 2001-10-25 2009-02-04 杰南技术公司 糖蛋白组合物
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003063893A2 (en) 2002-01-31 2003-08-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8093357B2 (en) * 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7749753B2 (en) 2002-04-09 2010-07-06 Kyowa Hakko Kirin Co., Ltd Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
JPWO2003084569A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物含有医薬
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
PL373256A1 (en) 2002-04-09 2005-08-22 Kyowa Hakko Kogyo Co, Ltd. Cells with modified genome
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
KR100493460B1 (ko) 2002-08-29 2005-06-07 재단법인서울대학교산학협력재단 암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
CA2766627C (en) * 2003-05-02 2019-12-03 Xencor, Inc. Optimized fc variants and methods for their generation
CA2542046A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Fused protein composition
WO2005035778A1 (ja) 2003-10-09 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. α1,6-フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法
DE602004032370D1 (de) * 2003-10-16 2011-06-01 Imclone Llc Fibroblasten-wachstumsfaktor-1-hemmer und behandlungsverfahren dafür
ES2630224T3 (es) 2003-10-22 2017-08-18 Keck Graduate Institute Métodos para sintetizar polipéptidos heteromultiméricos en levadura con el uso de una estrategia de apareamiento haploide
RS55723B1 (sr) 2003-11-05 2017-07-31 Roche Glycart Ag Molekuli koji se vezuju za antigen sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
US20070248605A1 (en) 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
BRPI0508761A (pt) 2004-03-31 2007-08-14 Genentech Inc anticorpo humanizado, composição que compreende um anticorpo humanizado, ácido nucléico isolado, vetor, célula hospedeira, processo de produção de anticorpo humanizado, método de tratamento de disfunção tgf-beta, método de detecção de tgf-beta, artigo industrializado e método de tratamento de cáncer
WO2005115363A2 (en) 2004-05-25 2005-12-08 Yale University Method for treating skeletal disorders resulting from fgfr malfunction
AU2006207999A1 (en) 2005-01-27 2006-08-03 Five Prime Therapeutics, Inc. Leader sequences for directing secretion of polypeptides and methods for production thereof
MX2007009940A (es) * 2005-02-18 2007-10-10 Medarex Inc Anticuerpos monoclonales que carecen de residuos fucosilo contra cd30.
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2007134210A2 (en) 2006-05-12 2007-11-22 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
CA2655246A1 (en) * 2006-06-09 2007-12-21 University Of Maryland, Baltimore Glycosylation engineered antibody therapy
CA2655504A1 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
ME02371B (me) 2006-09-29 2016-06-20 Oncomed Pharm Inc Sastojci i postupci za dijagnstikovanje i tretman raka
EP2094733A1 (en) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
ES2538990T3 (es) 2007-01-24 2015-06-25 Kyowa Hakko Kirin Co., Ltd. Composición de anticuerpo genéticamente recombinante que tiene una actividad efectora mejorada
ES2600882T3 (es) 2007-03-23 2017-02-13 The Translational Genomics Research Institute Procedimiento de clasificación del cáncer de endometrio
CA2682382A1 (en) * 2007-03-28 2008-10-09 Biogen Idec Inc. Non-fucosylated antibodies
US20110091473A1 (en) 2007-10-22 2011-04-21 Genmab A/S Novel antibody therapies
US9260525B2 (en) 2008-02-04 2016-02-16 Xiao-Jia Chang Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
WO2009100105A2 (en) 2008-02-04 2009-08-13 Attogen Inc. Inhibitors of oncogenic isoforms and uses thereof
WO2012021841A2 (en) 2010-08-12 2012-02-16 Attogen Inc. Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US8688158B2 (en) 2008-03-26 2014-04-01 Nec Corporation Radio resource control method, radio station apparatus, recording medium storing radio station control program, and radio communication system
CA2727247A1 (en) * 2008-06-10 2009-12-17 University Of Southern California Thymidylate synthase haplotype is associated with tumor recurrence in stage ii and stage iii colon cancer patients
EP2177615A1 (en) 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
JP5627591B2 (ja) * 2008-11-07 2014-11-19 ギャラクシー バイオテック， エルエルシー 線維芽増殖因子受容体２に対するモノクローナル抗体
US20120301482A1 (en) 2009-08-25 2012-11-29 National Jewish Health Methods and compositions for treatment of lung injury
BR112012007760A2 (pt) * 2009-10-07 2015-08-25 Macrogenics Inc Método de atenuar fucosilação pós translacional de uma região fc de igc humana, anticorpo que se liga especificamente a um antigeno de câncer caracteristico de um cancêr polipeptideo
US8664365B2 (en) * 2009-10-14 2014-03-04 Kalobios Pharmaceuticals, Inc. Antibodies to EphA3
CN102762221A (zh) 2010-01-14 2012-10-31 耶鲁大学 受体酪氨酸激酶(rtk)的抑制剂及其使用方法
US9140689B2 (en) 2010-03-14 2015-09-22 Translational Genomics Research Institute Methods of determining susceptibility of tumors to tyrosine kinase inhibitors
CA2800311A1 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2012045085A1 (en) * 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
JP2015505850A (ja) 2011-12-14 2015-02-26 シアトル ジェネティックス， インコーポレイテッド 新規な抗体薬物コンジュゲート（ａｄｃ）およびそれらの使用
PL2831110T3 (pl) * 2012-03-30 2018-11-30 The Regents Of The University Of California Terapia anty-EMP2 zmniejsza ilość rakowych komórek macierzystych
JP6188681B2 (ja) 2012-04-09 2017-08-30 第一三共株式会社 抗ｆｇｆｒ２抗体
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
EA037351B8 (ru) 2012-05-15 2021-04-29 Бристол-Майерс Сквибб Компани Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
CN104619840A (zh) 2012-07-05 2015-05-13 日本国立癌症研究中心 Fgfr2融合基因
WO2014089193A1 (en) 2012-12-04 2014-06-12 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9415118B2 (en) 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
BR112015027607A8 (pt) 2013-05-01 2018-01-23 Five Prime Therapeutics Inc métodos de tratamento de câncer de mama, de câncer da próstata, de câncer carcinoide, de câncer do ovário e de câncer do pulmão em pacientes.
EP3008210B1 (en) 2013-06-13 2020-10-07 University Of South Australia Methods for detecting prostate cancer
NZ715201A (en) 2013-08-01 2021-12-24 Five Prime Therapeutics Inc Afucosylated anti-fgfr2iiib antibodies
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015210886A1 (en) 2014-01-29 2016-09-01 Caris Mpi, Inc. Molecular profiling of immune modulators
MX2017003478A (es) 2014-11-05 2018-02-01 Genentech Inc Anticuerpos anti-fgfr2/3 y metodos para su uso.
WO2016100882A1 (en) 2014-12-19 2016-06-23 Novartis Ag Combination therapies
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA3004794A1 (en) 2015-11-23 2017-06-01 Five Prime Therapeutics, Inc. Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
SG10202112636SA (en) 2017-05-16 2021-12-30 Five Prime Therapeutics Inc Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment

Also Published As

Publication number Publication date
PH12016500137A1 (en) 2016-04-18
JP2023018049A (ja) 2023-02-07
RU2019125027A3 (enExample) 2020-02-28
DK3027651T3 (en) 2019-04-15
CA2915665C (en) 2020-07-28
PH12019501393B1 (en) 2022-09-07
LT3708583T (lt) 2022-04-11
US12465636B2 (en) 2025-11-11
HUE058243T2 (hu) 2022-07-28
DK3708583T3 (da) 2022-05-16
SI3027651T1 (sl) 2019-05-31
JP6860342B2 (ja) 2021-04-14
ME03476B (me) 2020-01-20
SG11201600767UA (en) 2016-03-30
LT3027651T (lt) 2019-04-10
JP2022078080A (ja) 2022-05-24
NZ715201A (en) 2021-12-24
PE20210949A1 (es) 2021-05-24
KR20250099279A (ko) 2025-07-01
AU2025203545A1 (en) 2025-06-05
AU2021245169B2 (en) 2025-02-20
EP3708583A1 (en) 2020-09-16
TWI679021B (zh) 2019-12-11
BR112015032789A2 (pt) 2017-11-07
TWI633120B (zh) 2018-08-21
AU2021245169A1 (en) 2021-11-04
US20150050273A1 (en) 2015-02-19
IL243409A0 (en) 2016-03-31
RU2698061C2 (ru) 2019-08-21
KR20160030578A (ko) 2016-03-18
MY184628A (en) 2021-04-10
PE20160190A1 (es) 2016-04-28
CN105452296A (zh) 2016-03-30
HUE043815T2 (hu) 2019-09-30
MX2020009223A (es) 2020-10-14
JP2020040955A (ja) 2020-03-19
AU2014296174A1 (en) 2016-01-21
RU2016106101A (ru) 2017-09-06
TW201536804A (zh) 2015-10-01
PH12021552742A1 (en) 2022-05-23
IL243409B (en) 2019-10-31
ES2913291T3 (es) 2022-06-01
KR102825701B1 (ko) 2025-06-27
MX374785B (es) 2025-03-06
CN105452296B (zh) 2020-09-25
EP4036118A1 (en) 2022-08-03
US20160339100A1 (en) 2016-11-24
US20190175730A1 (en) 2019-06-13
AU2019206039A1 (en) 2019-08-01
CL2018002291A1 (es) 2018-09-14
CL2016000221A1 (es) 2016-07-08
US10172937B2 (en) 2019-01-08
AU2019206039B2 (en) 2021-07-08
HK1220211A1 (en) 2017-04-28
CN112225810A (zh) 2021-01-15
KR102516152B1 (ko) 2023-03-31
RS58719B1 (sr) 2019-06-28
AU2014296174B2 (en) 2019-05-02
CY1121517T1 (el) 2020-05-29
JP2016527273A (ja) 2016-09-08
RU2740714C2 (ru) 2021-01-20
KR20230047508A (ko) 2023-04-07
CA2915665A1 (en) 2015-02-05
WO2015017600A1 (en) 2015-02-05
SI3708583T1 (sl) 2022-05-31
TW201906629A (zh) 2019-02-16
RU2019125027A (ru) 2019-08-19
PL3027651T3 (pl) 2019-08-30
EP3027651A1 (en) 2016-06-08
PT3708583T (pt) 2022-05-13
EP3708583B1 (en) 2022-03-02
JP7183136B2 (ja) 2022-12-05
MX2016001236A (es) 2016-05-24
US20250269016A1 (en) 2025-08-28
ZA201603218B (en) 2019-03-27
PL3708583T3 (pl) 2022-06-06
US11235059B2 (en) 2022-02-01
US20220168416A1 (en) 2022-06-02
EP3027651B1 (en) 2019-02-27
CY1125443T1 (el) 2024-12-13
PH12016500137B1 (en) 2019-12-04
PH12019501393A1 (en) 2020-09-14
JP2025118617A (ja) 2025-08-13
HRP20190502T1 (hr) 2019-05-03
ES2719103T3 (es) 2019-07-08
CN112225810B (zh) 2024-10-29

Similar Documents

Publication Publication Date Title
IL269528A (en) Anti- FCRH5 antibodies
ZA201603218B (en) Afucosylated anti-fgfr2iiib antibodies
GB201322583D0 (en) Antibodies
SG11201509361TA (en) Novel antibodies
ZA201601437B (en) Antibodies
GB201308658D0 (en) Antibodies
GB201315486D0 (en) Antibodies
IL245488B (en) Anti- ccl17 antibodies
GB201312226D0 (en) Improved antibodies
HK40044506B (zh) 无岩藻糖基化抗fgfr2iiib抗体
GB201318283D0 (en) Antibodies